Alpha Cognition (NASDAQ: ACOG) has signed an exclusive $44 million licensing agreement with China Medical System Holdings Limited (867.HK) to develop, manufacture, and commercialize ZUNVEYL (benzgalantamine) in Asia (excluding Japan), Australia, and New Zealand. ZUNVEYL, an FDA-approved treatment for mild-to-moderate Alzheimer’s disease, offers new hope in regions with a high prevalence of neurodegenerative disorders.
The deal includes $6 million in upfront payments and milestone-based fees. Alpha Cognition will also receive royalties on net sales. CMS will manage regulatory approvals and commercialization in the licensed regions.
Michael McFadden, CEO of Alpha Cognition, expressed confidence in CMS’s expertise, emphasizing the unmet need in territories where 50 million people are affected by Alzheimer’s. The partnership aims to bring an innovative therapy to underserved patients across the Asia-Pacific region.
